Alumis released top-line results from two Phase 3 trials showing envudeucitinib (an oral TYK2 inhibitor) met co-primary and key secondary endpoints in moderate-to-severe plaque psoriasis. The company reported high skin-clearing rates and consistent results across trials, triggering plans to pursue regulatory filings. The data thrust envudeucitinib into the competitive oral psoriasis class dominated by other TYK2 and small-molecule entrants. Alumis reported robust PASI and sPGA outcomes at week 16 with responses deepening over time. Management flagged the results as a catalyst for commercial positioning among oral therapies, and the company signaled readiness to prepare submissions toward approval pathways.